Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland

Human Vaccines

Volumn 7, Issue 7, 2011, Pages 749-756

  Szucs, Thomas D ^a   Kressig, Reto W ^a   Papageorgiou, Manto ^b   Kempf, Werner ^c   Michel, Jean Pierre ^d   Fendl, Anton ^e   Bresse, Xavier ^f  

^a UNIVERSITY OF BASEL   (Switzerland)

^b i3 Innovus   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e Sanofi Pasteur MSD   (Switzerland)

^f SANOFI PASTEUR   (France)

Author keywords

Cost effectiveness analysis; Health policy; Herpes zoster; Post herpetic neuralgia; Vaccination

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; ELDERLY CARE; FEMALE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH STATUS; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PREDICTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SWITZERLAND; VACCINATION;

AGED; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MODELS, THEORETICAL; NEURALGIA, POSTHERPETIC; SWITZERLAND; VACCINES, ATTENUATED;

EID: 79960811082     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.7.15573     Document Type: Article

References (25)

1. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23:490-6; PM:17575488.
2. Schiffner-Rohe J, Jow S, Köster I, Lilie M. Inzidenz von Herpes zoster HZ in Deutschland, abstract accepted by DEGAM 2009.
3. Richard JL, Zimmermann HP. Herpes Zoster 1998-2001. 2010.
4. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Micro 1993; 4:222-30. (Pubitemid 23321790)
5. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9; PM: 7618983.
6. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19:471-5; PM: 12356697.
7. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350-4; PM: 12441828.
8. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70:24-30; PM:12627483.
9. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PM:15930418.
10. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:241-51; PM: 8951917.
11. Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK 2010.
12. The Swiss Sentinel Surveillance Network 2010; http://www.bag.admin.ch/k- m-meldesystem/00736/00817/index.html?lang=en.
13. Federal statistics office of Switzerland 2010; http://www.bfs.admin.ch/ bfs/portal/en/index.html
14. Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland 2007.
15. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and postherpetic neuralgia in the United Kingdom. Epidemiol Infect 2008; 1-10; PM: 18466661.
16. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ 2000; 321:778-9; PM: 11009498.
17. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6:356-63; PM: 15943957.
18. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health 2001; 55:123-5. (Pubitemid 32095198)
19. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23:639-49; PM: 16173156.
20. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076-90; PM: 11312002.
21. Pellissier JM. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine 2007; 25:8326-37. (Pubitemid 350087379)
22. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998; 51:667-76; PM: 9743315.
23. Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24:1473-83; PM: 18413014.
24. Haldemann R, Luscher TF, Szucs TD. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study]. Praxis(Bern.1994.) 2001; 90:539-45; PM: 11550619.
25. Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland 2008.